Why this Wall Street hedge fund legend sold VRX and GILD?
This billion-dollar hedge fund initiates new position in struggling pharma TEVA as exits VRX.
Jim Simons, the founder of one of the world’s most successful hedge funds, is splashing out on controversial healthcare stock Valeant Pharmaceuticals (NYSE:VRX). …
BTIG’s Tim Chiang still spots challenges in VRX’s orbit, but likewise pinpoints strength in eyecare business Bausch + Lomb, which boasts robust international gains.
A Wall Street high-roller like Ken Griffin did not make it among the big leagues a.k.
Ken Griffin is a man known to be raring to take a risk when it is worthwhile, a daring and strategic mindset that …
One of the world’s top fund managers is backing volatile healthcare stocks VRX and MNKD.
Valeant Pharmaceuticals (NYSE:VRX) aced its third quarter, but while many on Wall Street were thrilled to see the biotech giant take a stride …
Deutsche Bank’s Gregg Gilbert is concerned about the unpredictability of VRX’s legal hurdles that lie ahead.
Israel “Izzy” Englander isn’t afraid to go against the market on TEVA, VRX and ACAD.
